



# **Tuberculosis Country Profile 2021 Afghanistan**

*Source: Global tuberculosis report 2021. Geneva: World Health Organization*

*Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.*

# Tuberculosis profile: Afghanistan

Population 2020: 39 million

## Estimates of TB burden\*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	75 000 (48 000-107 000)	193 (124-276)
HIV-positive TB incidence	13 (4-26)	0.03 (0.01-0.07)
HIV-negative TB mortality	11 000 (6 300-16 000)	27 (16-41)
HIV-positive TB mortality	130 (77-200)	0.34 (0.2-0.51)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2020	61% (43-95)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	15% (7-25)

## TB case notifications, 2020

Total new and relapse	45 818
- % tested with rapid diagnostics at time of diagnosis	26%
- % with known HIV status	65%
- % pulmonary	75%
- % bacteriologically confirmed <sup>^</sup>	68%
- % children aged 0-14 years	21%
- % women (aged ≥15 years)	46%
- % men (aged ≥15 years)	33%
Total cases notified	46 058

## TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	5	0.017%
- on antiretroviral therapy	5	100%

## Drug-resistant TB care\*\*, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases <sup>^</sup>	45%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases <sup>^</sup>	100%
Laboratory-confirmed cases - MDR/RR-TB <sup>^^</sup>	424
Patients started on treatment - MDR/RR-TB <sup>^^</sup>	375
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB <sup>^^</sup>	
Patients started on treatment - pre-XDR-TB or XDR-TB <sup>^^</sup>	27
MDR/RR-TB cases tested for resistance to any fluoroquinolone	207

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	91%	52 438
Previously treated cases, excluding relapse, registered in 2019		
HIV-positive TB cases registered in 2019		
MDR/RR-TB cases started on second-line treatment in 2018	69%	327
XDR-TB cases started on second-line treatment in 2018		


## TB preventive treatment, 2020

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	96% (89-100)


## TB financing

National TB budget, 2021 (US\$ millions)	11
- Funding source, domestic	
- Funding source, international	100%
- unfunded	0%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




## HIV-negative TB mortality (Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2020 (Number)



## Cases attributable to five risk factors, 2020 (Number)



## Total budget (US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.  
 \*\* RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone  
<sup>^</sup> Calculated for pulmonary cases only  
<sup>^^</sup> Includes cases with unknown previous TB treatment history  
<sup>^^^</sup> Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed